Table 1.
Baseline patient characteristics
| All patients (n=71) | |
|---|---|
| Age (years; mean ± SD) | 53.4 (±11.6) |
| Male (n, %) | 43 (60) |
| BMI (kg/m2; median; IQR) | 32.7 (28.1–38.1) |
| Type 2 Diabetes mellitus (n, %) | 25 (35) |
| Liver function tests; median (IQR) | |
| Bilirubin (μmol/L) | 10 (7–16) |
| ALT (IU/L) | 54 (30–76) |
| ALP (IU/L) | 172 (138–233) |
| Albumin (g/L) | 45 (44–47) |
| GGT (IU/L) | 66 (36–118) |
| AST (IU/L) | 40 (31–56) |
| Haematological tests; median (IQR) | |
| Platelet count (x109/l) | 208 (166–278) |
| Prothrombin time (s) | 13.6 (13.1–14.5) |
| Metabolic profile; median (IQR) | |
| Glucose (mmol/L) | 5.1 (4.8–6.3) |
| Cholesterol (mmol/L) | 4.7 (3.8–5.6) |
| HDL (mmol/L) | 1.1 (1.0–1.2) |
| LDL (mmol/L) | 2.7 (2.0–3.5) |
| Triglycerides (mmol/L) | 1.6 (1.2–2.4) |
| Histology (n, %) | |
| Fibrosis | |
| 0 | 5 (7) |
| 1 | 20 (28) |
| 2 | 20 (28) |
| 3 | 15 (21) |
| 4 | 11 (15) |
| Ballooning | |
| 0 | 17 (24) |
| 1 | 46 (65) |
| 2 | 8 (11) |
| Lobulitis | |
| 0 | 12 (17) |
| 1 | 58 (82) |
| 2 | 1 (1) |
| Steatosis | |
| 0 | 4 (6)a |
| 1 | 8 (11) |
| 2 | 17 (24) |
| 3 | 42 (59) |
| FLIP algorithm classification (n; %) | |
| Steatosis | 25 (35) |
| NASH | 46 (65) |
| Mild disease | 13 (18) |
| Significant disease | 58 (82) |
| Non‐invasive scores; median (IQR) | |
| cT1 (ms) | 923 (832–1035) |
| LIF score | 2.6 (1.5–3.3) |
| Liver stiffness (kPa; n=38) | 7.5 (5.1–13.3) |
FLIP, Fatty Liver Inhibition of Progression consortium; MR, magnetic resonance; cT1, iron‐corrected T1; LIF, liver inflammation and fibrosis.
a
Four patients with suspected NAFLD were found to have no steatosis on liver biopsy but still included as the absence of NAFLD could not have been predicted without liver biopsy.